HealthcareServices

Global Liver Diseases Therapeutics Industry Trends and Market Forecast 2026–2030

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the liver diseases therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Liver Diseases Therapeutics Market show for the 2026–2030 period?

The liver diseases therapeutics market has experienced substantial growth in recent years. Projections indicate it will expand from $15.18 billion in 2025 to $16.66 billion in 2026, at a compound annual growth rate (CAGR) of 9.8%. This historical growth can be attributed to several factors, including the high prevalence of viral hepatitis infections, an increase in alcohol-induced liver disease cases, early reliance on antiviral and supportive therapies, the limited treatment options available for chronic liver conditions, and the expansion of hospital-based liver care.

The liver diseases therapeutics market size is projected to experience substantial expansion in the coming years. This market is forecast to reach $24.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.9%. This anticipated growth during the forecast period is fueled by factors such as the increasing prevalence of metabolic liver diseases, the greater uptake of immunosuppressive and targeted therapeutic approaches, the expansion of treatment pipelines for liver cancer, a heightened understanding of the advantages of early intervention, and elevated healthcare expenditure on chronic liver conditions. Key trends emerging over the forecast horizon encompass a surge in demand for antiviral treatments for hepatitis, a sharpened focus on managing NAFLD and NASH, the increasing integration of immunotherapy in liver cancer treatment, the broadening scope of combination drug therapies, and a heightened priority placed on enduring disease management strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

What Drivers Are Shaping The Development Of The Liver Diseases Therapeutics Market?

The increasing occurrence of liver conditions is anticipated to fuel the expansion of the liver disease therapeutics market in the future. Liver disease encompasses any ailment impacting the liver, and therapeutics for liver diseases aid in managing these conditions through diverse treatment approaches. As an illustration, the Office for Health Improvement and Disparities, a UK-based government department, stated in December 2024 that premature deaths attributed to alcoholic liver disease saw a 3.6% rise in 2023, totaling 5,984, an increase from 5,776 in 2022. Consequently, the growing incidence of liver diseases is a primary driver for the expansion of the liver disease therapeutics market.

What Segment Types Are Examined In The Liver Diseases Therapeutics Market?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

How Are New Market Trends Shaping The Landscape Of The Liver Diseases Therapeutics Market?

Leading firms within the liver disease therapeutics market are concentrating on pioneering technologies, specifically artificial intelligence, to facilitate early detection of liver fibrosis in patients by clinicians during their disease advancement. The implementation of artificial intelligence in liver disease therapeutics involves utilizing sophisticated computational algorithms and machine learning approaches to process medical data, thereby assisting in prompt identification, accurate diagnosis, and tailored treatment plans for various liver conditions. An example of this is Predictive Health Intelligence, a UK-based healthcare information management enterprise, which introduced hepatoSIGHT in February 2023. This innovative AI-driven tool is capable of predicting liver fibrosis in individuals suffering from chronic liver disease. It functions as a case-finding and cohort mapping utility, specifically engineered to pinpoint patients susceptible to chronic liver disease (CLD). The system is secure, user-friendly, and intuitive, possessing the ability to rapidly scan millions of data lines in mere seconds to pinpoint patients who fulfill particular criteria. Furthermore, its capabilities encompass thorough data analysis, the application of machine learning algorithms, real-time risk assessment, and a straightforward interface.

Who Are The Top-Performing Companies In The Liver Diseases Therapeutics Market In Recent Years?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

How Does The Liver Diseases Therapeutics Market Perform Across Major Global Regions?

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Liver Diseases Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

Fatty Liver Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Liver Health Supplements Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795